Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stephens & Co. Maintains Overweight on Avid Bioservices, Lowers Price Target to $12

Author: Benzinga Newsdesk | March 11, 2024 11:00am
Stephens & Co. analyst Jacob Johnson maintains Avid Bioservices (NASDAQ:CDMO) with a Overweight and lowers the price target from $15 to $12.

Posted In: CDMO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist